Sign up
Pharma Capital

Preveceutical Medical announces advisory services deal with Stadnyk & Partners

Preveceutical will issue two million stock options to Stadnyk & Partners
1528217611_cq5dam.web.1200.Robotics-used-for-the-analysis.jpg
Stadnyk & Partners will provide strategic finance, merger and acquisition, and capital markets advisory services to Preveceutical

Health sciences company, PreveCeutical Medical Inc. (CSE:PREV) announced today that it has entered into an agreement with Stadnyk & Partners to provide strategic advisory services to the company.

The company will provide market awareness services to Preveceutical, and the company will issue two million stock options to Stadnyk & Partners. Of those options, one common share in the company may be acquired for C$0.08 per share for a period of 24 months. The initial agreement is for one year, subject to renewal by agreement of both parties. 

WATCH: PreveCeutical Medical Inc. receives first cannabis shipment at Australia lab

Stadnyk & Partners will provide strategic finance, merger and acquisition, and capital markets advisory services to Preveceutical to help it target its business goals during the terms of the agreement, for which three million stock options will be issued to Stadnyk & Partners. 

The founder of Stadnyk & Partners, David Stadnyk, has successfully initiated equity capital financing efforts of more than C$500mln. As an entrepreneur, he founded both private and public companies including: Pharmaxis, Eurpraxia Pharmaceuticals, Supreme Cannabis Company, Friday Night Inc and M Pharmaceutical Inc, among others.

Shares of Preveceutical were up 11.11% at C$0.10 on Tuesday. 

View full PREV profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.